Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://samuele914csp9.blazingblog.com/profile